Lili Nsongo's questions to Intellia Therapeutics Inc (NTLA) leadership • Q2 2025
Question
Lili Nsongo of Leerink Partners inquired about the target proportion of patients on stabilizers in the expanded ATTR-CM study, MAGNITUDE, and whether this was intended to ensure the trial is powered to show a combination benefit.
Answer
President and CEO John Leonard clarified that Intellia does not set a specific target for stabilizer use but anticipates it could be around 70%, reflecting the evolving standard of care. He confirmed the study expansion to 1,200 patients is designed to provide a more robust dataset and ensure a highly statistically significant finding for the combination of Nexi with stabilizers, which they view as a key commercial differentiator.